Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study

[1]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Moon,et al.  Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer. , 2019, Radiology.

[3]  Eun Sook Lee,et al.  Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold , 2018, Clinical breast cancer.

[4]  W. Moon,et al.  Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy. , 2018, Radiology.

[5]  K. K. van de Vijver,et al.  Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). , 2018, Breast.

[6]  Mitchell D Schnall,et al.  MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. , 2018, AJR. American journal of roentgenology.

[7]  W. Moon,et al.  Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour , 2018, European Radiology.

[8]  Bonnie N. Joe,et al.  Imaging Neoadjuvant Therapy Response in Breast Cancer. , 2017, Radiology.

[9]  G. Santamaría,et al.  Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response. , 2017, Radiology.

[10]  Tanya W. Moseley,et al.  A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy , 2017, Annals of surgery.

[11]  J. Wesseling,et al.  MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy , 2017, Breast Cancer Research and Treatment.

[12]  Kristine R Broglio,et al.  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. , 2016, JAMA oncology.

[13]  Mitchell D Schnall,et al.  Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. , 2016, Radiology.

[14]  H. Kuerer,et al.  Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials , 2016, Breast Cancer Research.

[15]  A. Schneeweiss,et al.  Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? , 2016, Annals of Surgical Oncology.

[16]  C. Kuhl,et al.  Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging. , 2015, Radiology.

[17]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[18]  M. Su.  Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017 , 2013 .

[19]  Les Irwig,et al.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.

[20]  Yeon-Hee Park,et al.  Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer , 2013, Annals of Surgical Oncology.

[21]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[22]  L. Esserman,et al.  Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.

[23]  A. Soran,et al.  MRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy? , 2011, Annals of Surgical Oncology.

[24]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Schmidt.  Meta-Analysis , 2008 .

[26]  Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer : Use as an Endpoint to Support Accelerated Approval , 2014 .

[27]  Title Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer : Translational breast cancer research consortium trial , 2022 .